We report a unique case of near fatal acute pulmonary oedema developing with intravenous ritodrine, given in an attempt to suppress premature labour. The novel aspect ofthe case is that the patient had also been treated in the previous week with high dose nebulized beta-agonists for an episode of acute severe asthma, demonstrating that this idiosyncratic reaction to beta-adrenergic agents only occurs with the intravenous route of administration. The management of acute severe asthma occurring in pregnancy is discussed with a review of previous literature regarding possible mechanisms of beta2-agonist-induced pulmonary oedema.
Introduction
Breathlessness is a common symptom during pregnancy, but is not thought to be due to increased airways resistance.' Nevertheless, asthmatic patients do occasionally deteriorate' and can pose therapeutic problems. Intravenous beta2-adrenoreceptor agonists including ritodrine,3 salbutamol,4'5 terbutaline, 6 fenoterol,7 and isoxuprine8 have been found to cause acute pulmonary oedema, occasionally fatal, when used as tocolytic agents, particularly with concurrent administration of corticosteroids to accelerate fetal lung maturation.
We report a patient with severe asthma during pregnancy, ventilated and treated uneventfully with nebulized salbutamol and corticosteroids, who, upon receiving parenteral ritodrine for premature labour, developed near fatal pulmonary oedema.
Case report
A 23 year old woman, 26 weeks pregnant, was admitted with acute severe asthma. Despite regular inhaled salbutamol, beclomethasone, disodium cromoglycate and oral aminophylline, she had become increasingly symptomatic throughout pregnancy. In the past, she had required multiple admissions for her asthma, but had never required positive pressure ventilation. There was a previous history of episodic angiooedema. She was pyrexial 38TC, with a tachycardia of 140 beats/min, and 25 mmHg of paradox, peak expiratory flow rate (PEFR) was 70 litres/min and arterial blood gases (Fio2 = 70%) showed pH = 7.23, P02 = 163 mmHg (21.7 kPa), Pco2 = 45 mmHg (6 kPa) and HCO3 = 18 mmol/l. A chest radiograph showed only hyperinflation ( Figure 1 ).
Despite intensive bronchodilator treatment she deteriorated, the Pco2 rising to 55 mmHg (7.3 kPa), and within one hour of admission elective endotracheal intubation and ventilation was undertaken. In addition to positive pressure ventilation (Engstrom Erica, Sweden) at a minute volume of 9.6 litres, nebulized salbutamol (5 mg) and ipratropium bromide (0.25 mg) 4 hourly, hydrocortisone 200 mg 4 times a day and intravenous aminophylline achieving plasma levels of 11 mg/l were continued. The initial peak inspiratory pressure was 55 cm H20, falling to 30 cm H2O after 24 hours.
The Pco2 was maintained at 30 mmHg (4 kPa), approximating to 'normal' levels during pregnancy', the Po2 averaging 100 mmHg (Fio2 = 40%). She was weaned off the ventilator after 8 days, and maintained on nebulized salbutamol 5 mg, 5 No direct effect of beta-agonists on pulmonary vascular permeability has been reported, but direct cardiotoxicity is suggested.l3 Up to 55% of patients treated with ritodrine develop transient T wave inversion, independently of induced hypokalaemia. Subendocardial myocardial infarction has also been reported. '3 In our case the enzyme rise was probably secondary to insertion ofa central line, although with a persistent electrocardiographic abnormality, a small infarct can-not be excluded. The normal echocardiogram, however, militates against left ventricular dysfunction as the cause of the pulmonary oedema.
To our knowledge, pulmonary oedema complicating intravenous beta2-agonist therapy is unique to pregnancy and the puerperium with no reported cases consequent upon their administration by either the nebulized or intravenous routes, in the treatment of acute asthma. Although larger intravenous doses are generally recommended for tocolytic therapy, the dosage schedules overlap, and pulmonary oedema has been reported at doses commonly employed in the treatment of acute asthma. 46 A severe deterioration of asthma during pregnancy is likely to be treated with corticosteroids, with the potential development of pulmonary oedema, if betaagonists are administered intravenously. Since nebulized and intravenous beta-agonists are equally effective,'4 it would seem preferable to use the inhaled route in the treatment of asthma during pregnancy, to circumvent this potentially fatal iatrogenic complication.
